# A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Recurrent or Metastatic Cervical Cancer

> **NCT03676959** · PHASE1 · UNKNOWN · sponsor: **Lee's Pharmaceutical Limited** · enrollment: 101 (estimated)

## Conditions studied

- Cervical Cancer

## Interventions

- **DRUG:** ZKAB001 5mg/kg
- **DRUG:** ZKAB001 10mg/kg
- **DRUG:** ZKAB001 15mg/kg

## Key facts

- **NCT ID:** NCT03676959
- **Lead sponsor:** Lee's Pharmaceutical Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-08-16
- **Primary completion:** 2022-05-15
- **Final completion:** 2022-10-15
- **Target enrollment:** 101 (ESTIMATED)
- **Last updated:** 2021-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03676959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03676959, "A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Recurrent or Metastatic Cervical Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03676959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*